본문 바로가기
KERD
논문KCI 등재

Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer

정익주|홍영선|고윤호|오소연|김태유|조하나|송은기|장대영|김종광|이경희|강병욱|백진호|구동회|이근욱|김진원|송홍석
대한암학회 (Korean Cancer Association)|2019.01|Cancer Research and Treatment|제51권 제1호|pp. 223-239

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

Quality of lifeAdvanced gastric cancerFirst-line palliative chemotherapy
주제분류의학일반

초록

Purpose The purpose of this study was to evaluate chemotherapy patterns and changes in quality of life (QOL) during first-line palliative chemotherapy for Korean patients with unresectable or metastatic/recurrent gastric cancer (GC). Materials and Methods This was a non-interventional, multi-center, prospective, observational study of 527 patients in Korea. QOL assessments were conducted using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 and QLQ-STO22 every 3 months over a 12-month period during first-line palliative chemotherapy. The specific chemotherapy regimens were selected by individual clinicians. Results Most patients (93.2%) received combination chemotherapy (mainly fluoropyrimidine plus platinum) as their first-line palliative chemotherapy. The median progression-free survival and overall survival were 8.2 and 14.8 months, respectively. Overall, “a little” changes (differences of 5-10 points from baseline) were observed in some of the functioning or symptom scales; none of the QOL scales showed either “moderate” or “very much” change (i.e.,  11 point difference from baseline). When examining the best change in each QOL domain from baseline, scales related to some aspects of functioning, global health status/QOL, and most symptoms revealed significant improvements (p < 0.05). Throughout the course of first-line palliative chemotherapy, most patients’ QOL was maintained to a similar degree, regardless of their actual response to chemotherapy. Conclusion This observational study provides important information on the chemotherapy patterns and QOL changes in Korean patients with advanced GC. Overall, first-line palliative chemotherapy was found to maintain QOL, and most parameters showed an improvement compared with the baseline at some point during the course.

Abstract

Purpose The purpose of this study was to evaluate chemotherapy patterns and changes in quality of life (QOL) during first-line palliative chemotherapy for Korean patients with unresectable or metastatic/recurrent gastric cancer (GC). Materials and Methods This was a non-interventional, multi-center, prospective, observational study of 527 patients in Korea. QOL assessments were conducted using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 and QLQ-STO22 every 3 months over a 12-month period during first-line palliative chemotherapy. The specific chemotherapy regimens were selected by individual clinicians. Results Most patients (93.2%) received combination chemotherapy (mainly fluoropyrimidine plus platinum) as their first-line palliative chemotherapy. The median progression-free survival and overall survival were 8.2 and 14.8 months, respectively. Overall, “a little” changes (differences of 5-10 points from baseline) were observed in some of the functioning or symptom scales; none of the QOL scales showed either “moderate” or “very much” change (i.e.,  11 point difference from baseline). When examining the best change in each QOL domain from baseline, scales related to some aspects of functioning, global health status/QOL, and most symptoms revealed significant improvements (p < 0.05). Throughout the course of first-line palliative chemotherapy, most patients’ QOL was maintained to a similar degree, regardless of their actual response to chemotherapy. Conclusion This observational study provides important information on the chemotherapy patterns and QOL changes in Korean patients with advanced GC. Overall, first-line palliative chemotherapy was found to maintain QOL, and most parameters showed an improvement compared with the baseline at some point during the course.

참고문헌 (30)

  1. Ferlay J, "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
  2. 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014", Cancer Research and Treatment, 49(2), pp.292~305 (2017), 대한암학회
  3. Digklia A, "Advanced gastric cancer : current treatment landscape and future perspectives", World J Gastroenterol, 22, pp.2403~2414 (2016)
  4. Glimelius B, "Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer", Ann Oncol, 8, pp.163~168 (1997)
  5. Pyrhonen S, "Randomised comparison of fluorouracil, epidoxorubicin and methotrexate(FEMTX)plus supportive care with supportive care alone in patients with non-resectable gastric cancer", Br J Cancer, 71, pp.587~591 (1995)
  6. Pavlakis N, "Regorafenib for the Treatment of Advanced Gastric Cancer(INTEGRATE) : a multinational placebo-controlled phase II trial", J Clin Oncol, 34, pp.2728~2735 (2016)
  7. Wilke H, "Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAINBOW) : a double-blind, randomised phase 3 trial", Lancet Oncol, 15, pp.1224~1235 (2014)
  8. Nieder C, "Early palliative care in patients with metastatic non-small cell lung cancer", Ann Palliat Med, 1, pp.84~86 (2012)
  9. 이준행, "Clinical Practice Guidelines for Gastric Cancer in Korea: An Evidence-Based Approach", Journal of Gastric Cancer, 14(2), pp.87~104 (2014), 대한위암학회[DOI]
  10. Bang YJ, "Registry of gastric cancer treatment evaluation(REGATE) : I baseline disease characteristics", Asia Pac J Clin Oncol, 10, pp.38~52 (2014)
  11. Ter-Ovanesov M, "Registry of gastric cancer treatment evaluation(REGATE) : II treatment practice", Asia Pac J Clin Oncol, 9, pp.373~380 (2013)
  12. Blazeby JM, "Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer", Eur J Cancer, 40, pp.2260~2268 (2004)
  13. Aaronson NK, "The European Organization for Research and Treatment of Cancer QLQ-C30 : a quality-of-life instrument for use in international clinical trials in oncology", J Natl Cancer Inst, 85, pp.365~376 (1993)
  14. Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
  15. Osoba D, "Interpreting the significance of changes in health-related quality-of-life scores", J Clin Oncol, 16, pp.139~144 (1998)
  16. Davidson M, "Current and future therapies for advanced gastric cancer", Clin Colorectal Cancer, 14, pp.239~250 (2015)
  17. Gebra Cuyun Carter, "Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea", Cancer Research and Treatment, 49(3), pp.578~587 (2017), 대한암학회
  18. Wagner AD, "Chemotherapy in advanced gastric cancer : a systematic review and meta-analysis based on aggregate data", J Clin Oncol, 24, pp.2903~2909 (2006)
  19. Van Cutsem E, "Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group", J Clin Oncol, 24, pp.4991~4997 (2006)
  20. Wagner AD, "Chemotherapy for advanced gastric cancer", Cochrane Database Syst Rev, 8, pp.CD004064~ (2017)
  21. Cho YH, "Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil", leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer, 2012, pp.15, 389~395
  22. 김영생, "Oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX-4) Combination Chemotherapy as a Salvage Treatment in Advanced Gastric Cancer", Cancer Research and Treatment, 42(1), pp.24~29 (2010), 대한암학회
  23. Kang JH, "Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone", J Clin Oncol, 30, pp.1513~1518 (2012)
  24. Kim HS, "Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer : a meta-analysis", Ann Oncol, 24, pp.2850~2854 (2013)
  25. Lee KW, "Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer", J Cancer Res Clin Oncol, 142, pp.687~697 (2016)
  26. Hwang IG, "A multi-center, open-label, randomized phase III trial of firstline chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer", J Geriatr Oncol, 8, pp.170~175 (2017)
  27. Saif MW, "Gastric cancer in the elderly : an overview", Eur J Surg Oncol, 36, pp.709~717 (2010)
  28. Wang J, "A prognostic model in metastatic or recurrent gastric cancer patients with good performance status who received first-line chemotherapy", Transl Oncol, 9, pp.256~261 (2016)
  29. Kim JW, "The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6regimen", Anticancer Res, 32, pp.1547~1553 (2012)
  30. Al-Batran SE, "Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma", Ann Oncol, 27, pp.673~679 (2016)

이 간행물의 다른 논문 (39건)

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial김봉석, 장대영, 라선영, 김기향, 강석윤, 이문희, 정현철, 정민규, 형우진, 이충근, 김효송, 정재호, 신동복, 정인경, 이경희, 노성훈pp. 1-11The Effect of Hospital Case Volume on Clinical Outcomes in Patients with Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Analysis (KROG-1106)김진호, 노재명, 이종훈, 김성환, 최진화, 김연실, 김원택, 오영택, 강민규, 김진희, 조관호, 이창걸, 김지윤, 문성호, 조문준, 안용찬, 금기창, 우홍균, 오동률, 하보람, 계철승pp. 12-23Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma김명진, 최진영, 박미숙, 이진용, 한경화, 강창무, 정용은, 김혜진pp. 24-33The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy EraSi-Yang Wang, Dong-Mei Mai, Yu-Yun Du, Dong-Hua Luo, Hao-Yuan Mo, Wang-Jian Zhang, Wayne R. Lawrence, Ya-Nan Jin, Xiu-Yu Cai, Mei-Su Lipp. 34-42Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)손주혁, 정경해, 박연희, 이경훈, 김태용, 박인혜, 이수이, 임석아, 노정실, 박경화, 김지현, 심성훈, 이근석, 안진희, 김성배, 남병호, 김희준pp. 43-52
원문 보기